meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1) 2
mCRC - 2nd line (L2) 3
endometrial cancer 10

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
NCT03015129, 2023	randomized controlled trial		phase 2 study	Rubinstein MM Gynecol Oncol 2023; 169:64-69-. 10.1016/j.ygyno.2022.11.028

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -